ESR1 and cancer: In early clinical trials, decitabine did not show a major therapeutic effect when administered as monotherapy, however, preclinical and clinical studies of different cancer entities showed evidence of a synergistic effect of decitabine in combination with HDACIs to restore ERα expression and sensitize ER-negative BCs to hormone therapy or chemotherapy [33, 34].